Browse TMEM176B

Summary
SymbolTMEM176B
Nametransmembrane protein 176B
Aliases LR8; MS4B2; LR8-like protein; Protein LR8
Chromosomal Location7q36.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus membrane Multi-pass membrane protein
Domain PF04103 CD20-like family
Function

May play a role in the process of maturation of dendritic cells. Required for the development of cerebellar granule cells (By similarity).

> Gene Ontology
 
Biological Process GO:0002521 leukocyte differentiation
GO:0002683 negative regulation of immune system process
GO:0097028 dendritic cell differentiation
GO:1902105 regulation of leukocyte differentiation
GO:1902106 negative regulation of leukocyte differentiation
GO:1903706 regulation of hemopoiesis
GO:1903707 negative regulation of hemopoiesis
GO:2001198 regulation of dendritic cell differentiation
GO:2001199 negative regulation of dendritic cell differentiation
Molecular Function -
Cellular Component GO:0005635 nuclear envelope
GO:0031965 nuclear membrane
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolTMEM176B
Nametransmembrane protein 176B
Aliases LR8; MS4B2; LR8-like protein; Protein LR8
Chromosomal Location7q36.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between TMEM176B and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolTMEM176B
Nametransmembrane protein 176B
Aliases LR8; MS4B2; LR8-like protein; Protein LR8
Chromosomal Location7q36.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of TMEM176B in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolTMEM176B
Nametransmembrane protein 176B
Aliases LR8; MS4B2; LR8-like protein; Protein LR8
Chromosomal Location7q36.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of TMEM176B in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.0350.943
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)6501
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.0710.97
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.9060.0312
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.5510.775
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 471.3550.574
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.3220.566
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.3320.835
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.1770.927
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.2760.925
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.5960.895
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.1620.371
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of TMEM176B in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277301.4-1.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275901.7-1.71
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.85.9-1.11
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.79.1-1.41
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.305.30.507
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.109.10.519
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolTMEM176B
Nametransmembrane protein 176B
Aliases LR8; MS4B2; LR8-like protein; Protein LR8
Chromosomal Location7q36.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of TMEM176B. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolTMEM176B
Nametransmembrane protein 176B
Aliases LR8; MS4B2; LR8-like protein; Protein LR8
Chromosomal Location7q36.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of TMEM176B. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by TMEM176B.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolTMEM176B
Nametransmembrane protein 176B
Aliases LR8; MS4B2; LR8-like protein; Protein LR8
Chromosomal Location7q36.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of TMEM176B. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolTMEM176B
Nametransmembrane protein 176B
Aliases LR8; MS4B2; LR8-like protein; Protein LR8
Chromosomal Location7q36.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of TMEM176B expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolTMEM176B
Nametransmembrane protein 176B
Aliases LR8; MS4B2; LR8-like protein; Protein LR8
Chromosomal Location7q36.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between TMEM176B and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolTMEM176B
Nametransmembrane protein 176B
Aliases LR8; MS4B2; LR8-like protein; Protein LR8
Chromosomal Location7q36.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting TMEM176B collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.